H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aslan Pharmaceuticals Ltd (ASLN) today and set a price target of $8.50. The company’s shares closed on Friday at $4.29.
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.9% and a 32.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on Aslan Pharmaceuticals Ltd is a Moderate Buy with an average price target of $8.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.44 and a one-year low of $2.51. Currently, Aslan Pharmaceuticals Ltd has an average volume of 26.77K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002.
